| Abstrakt: |
A recent study conducted by the Wistar Institute of Anatomy and Biology in Philadelphia, Pennsylvania, has explored the potential of biologics in treating ovarian cancer. The researchers focused on a surface antigen called Siglec-7 and developed human antibodies against it. These antibodies were found to enhance the killing of ovarian cancer cells by natural killer (NK) cells. Additionally, the researchers engineered an NK cell engager (NKCE) that simultaneously engaged NK cells and ovarian cancer targets, resulting in improved tumor control and survival in mice. The study suggests that targeting Siglec-7 could be a promising strategy for treating ovarian cancer and other difficult-to-treat cancers. [Extracted from the article] |
